EUVIMEDEUVIMED entdecken
ValidierungsstudieOpen Access · CC BY 4.0

Identification and validation of anti-protein arginine methyltransferase 5 (PRMT5) antibody as a novel biomarker for systemic sclerosis (SSc)

Minrui Liang, Lingbiao Wang, Xiaolong Tian, Kun Wang, Xiaoyi Zhu, Linlin Huang, Qing Li, Wenjing Ye, Chen Chen, Haihua Yang, Wanqing Wu, Xiangjun Chen und 9 weitere

Annals of the Rheumatic Diseases · 2024

DOI: 10.1136/ard-2024-225596 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Annals of the Rheumatic Diseases, 2024. Verfasst von Minrui Liang und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Huashan Hospital, Fudan University, Shanghai, China mliang10@fudan.edu.cn tlying@fudan.edu.cn zhou_feng@fudan.edu.cn. Hauptthemen laut MEDLINE: Autoantibodies, Protein-Arginine N-Methyltransferases, Scleroderma, Systemic. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: In the complex panorama of autoimmune diseases, the characterisation of pivotal contributing autoantibodies that are involved in disease progression remains challenging. This study aimed to employ a global antibody profiling strategy to identify novel antibodies and investigate their association with systemic sclerosis (SSc). METHODS: We implemented this strategy by conducting immunoprecipitation (IP) following on-bead digestion with the sera of patients with SSc or healthy donors, using antigen pools derived from cell lysates. The enriched antigen-antibody complex was proceeded with mass spectrometry (MS)-based quantitative proteomics and over-represented by bioinformatics analysis. The candidate antibodies were then orthogonally validated in two independent groups of patients with SSc. Mice were immunised with the target antigen, which was subsequently evaluated by histological examination and RNA sequencing. RESULTS: The IP-MS analysis, followed by validation in patients with SSc, revealed a significant elevation in anti-PRMT5 antibodies among patients with SSc. These antibodies exhibited robust diagnostic accuracy in distinguishing SSc from healthy controls and other autoimmune conditions, including systemic lupus erythematosus and Sjögren's syndrome, with an area under the curve ranging from 0.900 to 0.988. The elevation of anti-PRMT5 antibodies was verified in a subsequent independent group with SSc using an additional method, microarray. Notably, 31.11% of patients with SSc exhibited seropositivity for anti-PRMT5 antibodies. Furthermore, the titres of anti-PRMT5 antibodies demonstrated a correlation with the progression or regression trajectory in SSc. PRMT5 immunisation displayed significant inflammation and fibrosis in both the skin and lungs of mice. This was concomitant with the upregulation of multiple proinflammatory and profibrotic pathways, thereby underscoring a potentially pivotal role of anti-PRMT5 antibodies in SSc. CONCLUSIONS: This study has identified anti-PRMT5 antibodies as a novel biomarker for SSc.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AutoantibodiesProtein-Arginine N-MethyltransferasesScleroderma, SystemicHumansMiceBiomarkersFibrosisPulmonary FibrosisSkin DiseasesAnimals

Stichwörter der Autor:innen

AutoantibodiesAutoimmune DiseasesScleroderma, Systemic

Substanzen

AutoantibodiesBiomarkersPRMT5 protein, humanProtein-Arginine N-Methyltransferases

Autor:innen und Institutionen

  • Department of Rheumatology, Huashan Hospital, Fudan University, Shanghai, China mliang10@fudan.edu.cn tlying@fudan.edu.cn zhou_feng@fudan.edu.cn.
  • Institute of Rheumatology, Immunology and Allergy, Fudan University, Shanghai, China.
  • Huashan Rare Disease Center, Huashan Hospital, Fudan University, Shanghai, China.
  • Department of Rheumatology, Huashan Hospital, Fudan University, Shanghai, China.
  • Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS) and Shanghai Institute of Infectious Disease and Biosecurity, Shanghai Frontiers Science Center of Pathogenic Microorganisms and Infection, Shanghai Engineerin…
  • Shanghai Key Laboratory of Medical Epigenetics, International Co-laboratory of Medical Epigenetics and Metabolism, Ministry of Science and Technology, Institutes of Biomedical Sciences, Fudan University, Shanghai, China.

Förderung

  • Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences
  • National Natural Science Foundation of China

Zitieren

APA

Liang, M., Wang, L., Tian, X., Wang, K., Zhu, X., Huang, L., Li, Q., Ye, W., Chen, C., Yang, H., Wu, W., Chen, X., Zhu, X., Xue, Y., Wan, W., Wu, Y., Lu, L., Wang, J., Zou, H., …, & Zhou, F. (2024). Identification and validation of anti-protein arginine methyltransferase 5 (PRMT5) antibody as a novel biomarker for systemic sclerosis (SSc). Annals of the Rheumatic Diseases. https://doi.org/10.1136/ard-2024-225596

Vancouver

Liang M, Wang L, Tian X, Wang K, Zhu X, Huang L, et al. Identification and validation of anti-protein arginine methyltransferase 5 (PRMT5) antibody as a novel biomarker for systemic sclerosis (SSc). Annals of the Rheumatic Diseases. 2024. doi:10.1136/ard-2024-225596

BibTeX
@article{Liang2024,
  author = {Liang, Minrui and Wang, Lingbiao and Tian, Xiaolong and Wang, Kun and Zhu, Xiaoyi and Huang, Linlin and Li, Qing and Ye, Wenjing and Chen, Chen and Yang, Haihua and Wu, Wanqing and Chen, Xiangjun and Zhu, Xiaoxia and Xue, Yu and Wan, Weiguo and Wu, Yanling and Lu, Liwei and Wang, Jiucun and Zou, Hejian and Ying, Tianlei and Zhou, Feng},
  title = {Identification and validation of anti-protein arginine methyltransferase 5 (PRMT5) antibody as a novel biomarker for systemic sclerosis (SSc)},
  journal = {Annals of the Rheumatic Diseases},
  year = {2024},
  doi = {10.1136/ard-2024-225596}
}
Kostenlos starten →